Flecainide clinical trials
Flecainide is named as an intervention in 4 current clinical trials in our France, Belgium, Norway and South Korea registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Assistance Publique - Hôpitaux de Paris (1). The most-studied condition is Atrial Fibrillation (AF). The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Where Flecainide is approved
All regulators →Of the three regulators tracked here, the first to approve Flecainide was the US, on 31 Oct 1985.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Flecainide
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Flecainide works
All drug targets →- Sodium channel protein type V alpha subunit blocker BlockerTarget: SCN5A sodium voltage-gated channel alpha subunit 5ChEMBL only
- Supraventricular tachycardiaPhase 3
- Ventricular arrhythmiaPhase 3
- Atrial fibrillationPhase 3
- Atrial flutterPhase 3
- Coronary artery disorderPhase 3
- Andersen-Tawil syndromePhase 2
- Parkinson diseasePhase 2
- Premature ventricular contractionPhase 2
- Arrhythmogenic right ventricular cardiomyopathyPhase 2
- NarcolepsyPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL652, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 2560, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Flecainide
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 5 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Flecainide
- ATC code
- C01BC04
- ChEMBL
- CHEMBL652
- DrugBank
- DB01195
- PubChem CID
- 3356
- CAS number
- 54143-55-4
- FDA UNII
- K94FTS1806
- Wikidata
- Q421381
- Wikipedia
- Flecainide
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Flecainide
4 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Flecainide in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Flecainide. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
AVISO - Assessment of Flecainide versus Bisoprolol as First-Line Treatment for Premature Ventricular Contractions: a Multicenter Randomized Clinical Trial
2025-524584-20-00 · Cardiovascular Diseases
|
Phase 3 | Authorised | Assistance Publique Hopitaux De Paris | France |
Flecainide across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
5 single-substance products containing Flecainide on the HPRA medicines list.
- Flecainide 100mg TabletsTeva B.V. · PA1986/050/002 · Marketed
- Flecainide 50mg TabletsTeva B.V. · PA1986/050/001 · Marketed
- Tambocor 10 mg/ml Solution for Injection or InfusionViatris Healthcare Limited · PA23355/023/001 · Marketed
- Tambocor 100 mg TabletsViatris Healthcare Limited · PA23355/023/003 · Marketed
- Tambocor 50 mg TabletsViatris Healthcare Limited · PA23355/023/002 · Marketed
Supply shortages
No entry for Flecainide in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Flecainide
7 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Assistance Publique - Hôpitaux de Paris | 1 |
| Universitaire Ziekenhuizen KU Leuven | 1 |
| Oslo University Hospital | 1 |
| Inha University Hospital | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in France | 1 | 0 |
| Clinical trials in Belgium | 1 | 1 |
| Clinical trials in Norway | 1 | 0 |
| Clinical trials in South Korea | 1 | 0 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Flecainide trials
How many clinical trials are testing Flecainide?
4 current trials in our France, Belgium, Norway and South Korea registers name Flecainide (also registered as C01B C04) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Flecainide trials recruiting patients?
Yes. 1 of the 4 trials is recruiting: 1 with sites in Belgium. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Flecainide clinical trials?
Assistance Publique - Hôpitaux de Paris (1), Universitaire Ziekenhuizen KU Leuven (1), Oslo University Hospital (1) and Inha University Hospital (1). The number in brackets is how many trials each organisation leads.
Is Flecainide licensed in Ireland?
Yes. The HPRA medicines list includes 5 single-substance products containing Flecainide, for example Flecainide 100mg Tablets (Teva B.V.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Flecainide shortage?
Not in the lists we track: Flecainide has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Flecainide works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Flecainide works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Flecainide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.